December 23, 2016 / 7:17 AM / 7 months ago

BRIEF-Vectura signs deal with Mundipharma on respiratory treatments

1 Min Read

Dec 23 (Reuters) - Vectura Group Plc

* Global development programme with Mundipharma for PMDI inhaled triple therapy (VR2076) for asthma and COPD

* Exercise of this option triggers a payment to vectura of eur 1.5 million

* If Mundipharma decides to develop programme in COPD, Vectura eligible for further potential milestones of up to eur 20.0 million

* In December 2015, companies entered into a feasibility and option agreement

* Further total potential milestone payments up to eur 46.5 million are receivable linked to milestones, future net sales of product Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below